Top Page
Immuron Limited
(Frankfurt:IMC)
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Immuron Limited Business Overview & Revenue Model
Immuron Limited Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.90M | 1.80M | 765.19K | 145.78K | 2.52M |
| Gross Profit | 3.34M | 1.31M | 523.50K | 94.70K | 1.83M |
| EBITDA | -6.19M | -3.80M | -3.08M | -8.33M | -3.17M |
| Net Income | -6.94M | -3.79M | -2.85M | -8.38M | -2.93M |
Balance Sheet | |||||
| Total Assets | 15.55M | 21.99M | 24.86M | 27.05M | 6.20M |
| Cash, Cash Equivalents and Short-Term Investments | 11.66M | 18.99M | 22.11M | 25.05M | 3.25M |
| Total Debt | 173.50K | 189.09K | 209.79K | 20.50K | 61.10K |
| Total Liabilities | 2.84M | 2.37M | 1.68M | 1.16M | 558.25K |
| Stockholders Equity | 12.71M | 19.62M | 23.18M | 25.90M | 5.64M |
Cash Flow | |||||
| Free Cash Flow | -5.56M | -2.50M | -3.14M | -4.09M | -3.17M |
| Operating Cash Flow | -5.56M | -2.49M | -3.13M | -4.08M | -3.16M |
| Investing Cash Flow | 327.56K | -2.74M | -10.05K | -6.63K | -864.00 |
| Financing Cash Flow | 829.00 | -35.02K | -36.26K | 26.49M | 1.17M |
Immuron Limited Technical Analysis
Immuron Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$21.46M | ― | -52.70% | ― | 82.90% | -89.41% | |
54 Neutral | AU$73.17M | 26.83 | 26.99% | ― | ― | 51.85% | |
52 Neutral | $7.63B | 0.11 | -62.96% | 2.08% | 16.16% | 0.31% | |
46 Neutral | AU$2.23M | ― | -392.18% | ― | ― | 34.26% | |
46 Neutral | AU$14.28M | ― | -64.72% | ― | 139.19% | 33.33% | |
36 Underperform | AU$20.75M | ― | -42.50% | ― | ― | 80.96% | |
27 Underperform | AU$1.28M | ― | -147.32% | ― | ― | 26.09% |
Immuron Limited Corporate Events
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Coffee Microcaps Conference, highlighting the company’s innovative approaches in the biopharmaceutical industry. This presentation underscores Immuron’s commitment to advancing its platform technology and products like Travelan® and IMM-529, which have shown promise in treating travelers’ diarrhea and Clostridioides difficile infections, respectively. The announcement reflects the company’s ongoing efforts to strengthen its market position and expand its impact on global health through innovative treatments.
The Bank of New York Mellon Corporation (BNYMC) has increased its voting power in Immuron Limited from 34.17% to 42.69%, marking a significant change in its interest in the company. This increase in voting power could potentially impact Immuron’s strategic decisions and influence its market positioning, reflecting BNYMC’s growing influence and interest in the company’s operations.
Immuron Limited announced the cessation of 2,560,000 securities due to the expiry of options without exercise or conversion, effective July 21, 2025. This cessation may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth prospects.
Immuron Limited has announced the issuance of 32,909,640 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This strategic move reflects Immuron’s adherence to regulatory standards and may influence its market positioning by potentially increasing its capital base.
Immuron Limited has announced the application for the quotation of 32,909,640 ordinary fully paid securities on the Australian Securities Exchange (ASX) with the issue date set for July 21, 2025. This move is part of a previously announced transaction, which could potentially enhance the company’s market presence and provide additional capital for its ongoing and future projects, thereby impacting its operations and positioning within the biopharmaceutical industry.
Immuron Limited has announced a proposed issue of 32,909,640 ordinary fully paid securities, with the issue date set for July 18, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market position by increasing its capital base and providing funds for future operations or strategic initiatives.
Immuron Limited has issued 473,880 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as per the notice under section 708A(5)(e). The company confirms compliance with relevant provisions of the Corporations Act and states there is no ‘excluded information’ that needs to be disclosed, indicating transparency in its operations.
Immuron Limited has announced a proposed issue of 473,880 ordinary fully paid securities, with the issue date set for July 17, 2025. This move is part of a placement or other type of issue, indicating a strategic effort to raise capital, which could impact the company’s financial standing and market positioning.
Immuron Limited has issued 877,440 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as per the notice given under section 708A(5)(e). The company confirms compliance with relevant provisions of the Corporations Act and states that there is no excluded information required to be disclosed. This issuance could potentially impact Immuron’s financial structure and investor relations by increasing the number of shares available in the market.
Immuron Limited has announced the quotation of 877,440 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from July 17, 2025. This move is part of previously announced transactions and could potentially enhance the company’s market presence and liquidity, impacting its stakeholders positively.
Immuron Limited has announced a significant increase in sales for its over-the-counter immune supplement, Travelan, which targets pathogenic bacteria in the gastrointestinal tract. The company reported a 49% increase in global sales, reaching AUD $7.3 million for FY25, with notable growth in both the Australian and North American markets. This growth supports Immuron’s strategy to establish Travelan as a travel essential and highlights its strong market positioning, particularly in Australia where it is one of the fastest-growing pharmacy brands.
Immuron Limited has announced a change in the substantial holding of its shares by The Bank of New York Mellon Corporation (BNYMC) and its associated entities. The voting power of BNYMC Group in Immuron Limited has increased from 33.12% to 34.17%, indicating a slight increase in their influence over the company’s decisions. This change reflects BNYMC’s continued interest and investment in Immuron, potentially impacting the company’s strategic direction and stakeholder interests.
Immuron Limited has issued 116,680 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as per section 708A(5) of the Act. The company has complied with relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a transparent and compliant operation that may reassure stakeholders.
Immuron Limited is on track to surpass A$7 million in sales this financial year, marking a significant increase from the previous year’s A$4.9 million. The company is advancing several clinical trials, including Travelan® for traveler’s diarrhea, with results expected in October 2025, and plans to submit an IND for IMM-529 to the FDA in August 2025. Additionally, Immuron is preparing to launch ProIBS® in Australia, targeting the IBS treatment market. These developments could enhance Immuron’s market presence and strengthen its relationships with key stakeholders, including the US Department of Defense.
Immuron Limited has issued 135,800 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with the relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a transparent and compliant operational stance.
Immuron Limited has announced the application for quotation of 135,800 fully paid ordinary securities on the Australian Securities Exchange (ASX), with an issue date of May 29, 2025. This move is part of previously announced transactions and may enhance the company’s market presence and liquidity, potentially impacting its operations and stakeholder interests positively.
Immuron Limited has announced a proposed issue of 135,800 fully paid ordinary securities, with the issuance date set for May 29, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market positioning by increasing its capital base and enhancing its financial flexibility.